video thumbnail

Long COVID Improvement after Therapeutic Apheresis

Duration: 20:19

Write A New Comment


This study demonstrates the reduction in autoantibodies, inflammatory biomarkers, and erythrocyte rouleaux formation after extracorporeal apheresis. Possibly an important intervention for patients that are struggling with long COVID for a prolonged period of time and are refractory to other therapies.

Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis | Molecular Psychiatry

* Identify symptoms associated with Chronic Fatigue Syndrome.

* Understand the link between clinical improvement in Long COVID and reduction in autoantibodies, lipids, and inflammation through therapeutic Aphresis.

* Comprehend the details of a study on Chronic Fatigue Syndrome and post-exertional malaise.

* Recognize parameters collected in pre and post-Aphresis blood assessments.

* Learn the clinical assessment tools, including FACIT-F Questionnaire and visual analog scales.

* Understand the impact of Aphresis on biomarkers, including neurotransmitter autoantibodies, inflammatory factors, rheological factors, and lipid levels.

Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.


In addition to the presenter, following authors may have helped with the content writing, review, or approval:

  • Dr. Mobeen Syed

CME, CE, CEU and Other Credit Types:

ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Information

In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for Continuing Medical Education), we are committed to upholding principles of balance, independence, objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing Education (CE) activities. These policies include the careful management and mitigation of any relevant financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined that these relationships are not deemed inappropriate in the context of their respective presentations. Additionally, they are found to be consistent with the educational objectives and the integrity of the activity.

Faculty Disclosures
Dr. Mobeen Syed Author declares no conflict of interest.


Dr. Mobeen Syed

Dr. Mobeen Syed

Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.

Please login to access this content.

Don't have an account?

Start Your Free trial

No credit card information needed.

Chronic Inflammation

Related Videos